1. Home
  2. VATE vs VRCA Comparison

VATE vs VRCA Comparison

Compare VATE & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo INNOVATE Corp.

VATE

INNOVATE Corp.

HOLD

Current Price

$7.68

Market Cap

103.5M

Sector

Industrials

ML Signal

HOLD

Logo Verrica Pharmaceuticals Inc.

VRCA

Verrica Pharmaceuticals Inc.

HOLD

Current Price

$4.62

Market Cap

88.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VATE
VRCA
Founded
1994
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
103.5M
88.0M
IPO Year
1996
2018

Fundamental Metrics

Financial Performance
Metric
VATE
VRCA
Price
$7.68
$4.62
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$17.00
AVG Volume (30 Days)
93.8K
83.3K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,246,000,000.00
$35,577,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$94.44
P/E Ratio
N/A
N/A
Revenue Growth
12.55
370.22
52 Week Low
$3.75
$3.28
52 Week High
$21.30
$9.82

Technical Indicators

Market Signals
Indicator
VATE
VRCA
Relative Strength Index (RSI) 52.97 42.61
Support Level $6.48 $4.65
Resistance Level $8.20 $5.94
Average True Range (ATR) 0.48 0.28
MACD 0.20 -0.03
Stochastic Oscillator 88.28 21.95

Price Performance

Historical Comparison
VATE
VRCA

About VATE INNOVATE Corp.

Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. Its segments include Infrastructure, Life Sciences and Spectrum, and Other segment. Through its subsidiaries it provides fully integrated structural and steel construction services; supports healthcare and biotechnology product development; and operates Over-The-Air (OTA) broadcasting stations across the United States (U.S.) including Puerto Rico.

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

Share on Social Networks: